The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas

Breast Cancer Research and Treatment

Volumn 86, Issue 2, 2004, Pages 139-152

  Milde Langosch, Karin ^a   Röder, Heike ^a   Andritzky, Birte ^a   Aslan, Bahriye ^a   Hemminger, Gabriele ^a   Brinkmann, Anja ^a   Bamberger, Christoph M ^a   Löning, Thomas ^a   Bamberger, Ana Maria ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

AP 1; Breast cancer; c Fos; FosB; Fra 1; Fra 2; Invasion

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C FOS; PROTEIN FOS; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR FRA 2; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; EXPRESSION VECTOR; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-FOS; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 3342967781     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000032982.49024.71     Document Type: Article

References (25)

1. Karin M, Liu Z-G, Zandi E: AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246, 1997
2. Ryseck R-P, Bravo R: c-Jun, JunB, JunD differ in their binding affinities to AP-1 and CRE consensus sequences: effect of fos proteins. Oncogene 6: 533-542, 1991
3. Mechta F, Lallemand D, Pfarr CM, Yaniv M: Transformation by ras modifies AP-1 composition and activity. Oncogene 14: 837-847, 1997
4. Pospelova TV, Medvedev AV, Kukushkin AN, Svetlikova SB, van der Eb AJ, Dorsman JC, Pospelov VA: E1A + cHa-ras transformed rat embryo fibroblast cells are characterized by high and constitutive DNA binding activities of AP-1 dimers with significantly altered composition. Gene expr 8: 19-32, 1999
5. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ: cjun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18: 6063-6070, 1999
6. Soto U, Denk C, Finzer P, Hutter KJ, zur Hausen H, Rösl F: Genetic complementation to non-tumorigenicity in cervical-carcinoma cells correlates with alterations in AP-1 composition. Int J Cancer 86: 811-817, 2000
7. Vallone D, Battista S, Pierantoni GM, Fedele M, Casalino L, Santoro M, Viglietto G, Fusco A, Verde P: Neoplastic transformation of rat thyroid cells requires the JunB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J 16: 5310-5321, 1997
8. Bamberger A-M, Methner C, Lisboa BW, Städtler C, Schulte HM, Löning T, Milde-Langosch K: Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive phenotype. Int J Cancer 84: 553-558, 1999
9. Milde-Langosch K, Bamberger AM, Methner C, Rieck G, Löning T: Expression of cell cycle regulatory proteins Rb, p16/MTS1, p27/Kip1, p21/Waf1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members. Int J Cancer 87: 468-472, 2000
10. Andersen H, Mahmood S, Tkach V, Cohn M, Kustikova O, Grigorian M, Berezin V, Bock E, Lukanidin E, Tulchinsky E: The ability of Fos family members to produce phenotypic changes in epitheloid cells is not directly linked to their transactivation potentials. Oncogene 21: 4843-4848, 2002
11. Nandy A, Jenatschke S, Hartung B, Milde-Langosch K, Bamberger A-M, Gellersen B: Genomic structure and transcriptional regulation of the human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (PGDH) gene. Endocrinology, in press
12. Lawrence DA, Olson ST, Palaniappan S, Ginsburg D: Serpin reactive center loop mobilityis required for inhibitor function but not for enzyme recognition. J Biol Chem 269: 27657-27662, 1994
13. Milde-Langosch K, Kappes H, Riethdorf S, Löning T, Bamberger A-M: FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas. Breast Cancer Res Tr 77: 265-275, 2003
14. Kupferman ME, Fini ME, Muller WJ, Weber R, Cheng Y, Muschel RJ: Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression. Am J Pathol 157: 1777-1783, 2000
15. Toi M, Ishigaki S, Tominaga T: Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat 52: 113-124, 1998
16. Tulchinsky E: Fos family members: regulation, structure and role in oncogenic transformation. Histol Histopathol 15: 921-928, 2000
17. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A, Beauheim C, Harvey S, Ethier SP, Johnson PH: Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 61: 5168-5178, 2001
18. Fung LF, Lo AKF, Yuen PW, Liu Y, Wang XH, Tsao SW: Differential gene expression in nasopharyngeal carcinoma cells. Life Sci 67: 923-936, 2000
19. Zoumpourlis V, Papassava P, Linardopoulos S, Gillespie D, Balmain A, Pintzas A: High levels of phosphorylated c-jun, fra-1, fra-2, and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. Oncogene 19: 4011-4021, 2000
20. Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E, Tulchinsky E: Fra-1 induces morphological transformation and increases in vitro invasiveness and mobility of epithelioid adenocarcinoma cells. Mol Cell Biol 18: 7095-7105, 1998
21. Friedl P, Wolf K: Tumour-cell invasion and migration: diversity and escape mechanisms. Nature Rev 3: 362-374, 2003
22. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR: Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62: 3417-3427, 2002
23. Mechta-Grigoriou F, Gerald D, Yaniv M: The mammalian Jun proteins: redundancy and specificity. Oncogene 20: 2378-2389, 2001
24. Rinehart-Kim J, Johnston M, Birrer M, Bos T: Alterations in the gene expression profile of MCF-7 breast tumor cells in response to c-jun. Int J Cancer 88: 180-190, 2000
25. Briggs J, Chamboredon S, Castellazzi M, Kerry J-A, Bos T-J: Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 21: 7077-7091, 2002